Information de reference pour ce titreAccession Number: | 01714644-201805000-00004.
|
Author: | Bedi, Gillinder DPsych (Clin) 1,2
|
Institution: | (1)Department of Psychiatry, Columbia University Medical Center, New York, New York (2)Orygen National Centre of Excellence in Youth Mental Health, University of Melbourne, Parkville, Australia
|
Title: | |
Source: | JAMA Psychiatry. 75(5):419-420, May 2018.
|
References: | 1. Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (+/-3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol. 2013;27(1):40-52.
2. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of +/-3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25(4):439-452.
3. Holland J. Ecstasy: The Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester, VT: Park Street Press; 2001.
4. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev. 2003;55(3):463-508.
5. Cole JC. MDMA and the "Ecstasy paradigm". J Psychoactive Drugs. 2014;46(1):44-56.
6. Kamilar-Britt P, Bedi G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neurosci Biobehav Rev. 2015;57:433-446.
7. Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017;31(5):576-588.
|
Language: | English.
|
Document Type: | Opinion: Viewpoint.
|
ISSN: | 2168-622X
|
DOI Number: | https://dx.doi.org/10.1001/jamap...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |